Jul 1, 2026 09:02AM
Jul 1, 2026 09:00AM
Mar 30, 2023 04:08PM
Mar 30, 2023 04:05PM
Nov 3, 2022 07:33AM
Nov 3, 2022 07:30AM
Aug 12, 2022 07:16AM Aptinyx (APTX) Phase 2b Study of NYX-2925 in Fibromyalgia Did Not Achieve Statistically Significant Separation from Placebo
Aug 12, 2022 07:15AM
Aug 4, 2022 04:05PM
May 17, 2022 07:37AM
Apr 29, 2022 07:37AM
Apr 20, 2022 07:47AM
Apr 20, 2022 07:47AM
Apr 7, 2022 07:01AM Aptinyx (APTX) Reports Phase 2b Study of NYX-2925 Did Not Achieve Statistical Significance
Apr 7, 2022 07:00AM
Mar 23, 2022 04:05PM
Feb 28, 2022 07:25AM
Feb 9, 2022 07:00AM
Jan 6, 2022 07:37AM
Dec 16, 2021 07:37AM
Oct 27, 2021 06:47AM Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Aug 10, 2021 04:10PM
Jun 15, 2021 04:10PM
May 13, 2021 04:05PM
May 10, 2021 07:57AM
Apr 29, 2021 06:55AM
Apr 29, 2021 06:47AM
Mar 24, 2021 04:05PM Aptinyx Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Jan 19, 2021 08:31AM
Jan 4, 2021 07:59AM
Jan 4, 2021 07:57AM
Nov 12, 2020 04:03PM
Oct 21, 2020 09:27AM
Oct 20, 2020 05:33PM
Oct 19, 2020 04:45PM Aptinyx (APTX) Phase 2 Study of NYX-783 in Patients With Post-Traumatic Stress Disorder Achieves Primary Objective
Oct 19, 2020 04:44PM
Sep 28, 2020 08:27AM
Sep 28, 2020 08:27AM
Jul 8, 2020 08:37AM
Jun 18, 2020 07:59AM
Jun 18, 2020 07:57AM
Jun 18, 2020 07:57AM Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder
Mar 30, 2020 04:01PM
Mar 30, 2020 04:01PM
Dec 9, 2019 04:05PM
Dec 9, 2019 04:05PM
Nov 12, 2019 04:01PM
Nov 12, 2019 04:01PM
Nov 12, 2019 07:39AM Aptinyx (APTX) Begins Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
Nov 12, 2019 07:27AM

325,888 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All